Doc,
Not sure where you are getting your numbers from;
The New York Times
January 17, 2006
"And yet, a factor that limits Alli's (Xenical) potential for overuse is its tendency to cause flatulence, diarrhea or even sudden loss of bowel control.
Those side effects are among the reasons Xenical has never lived up to analysts' original forecasts.
"Worldwide sales quickly rose to nearly $750 million in 1999, the first year Xenical was available in the United States. As patients realized it was not an obesity cure-all, though, sales fell off and now hover at about $500 million a year worldwide, mainly outside the United States."
Allianz Se stock quotes
Allianz Se stock charts
Follow this thread
